Akebia Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
AKBA$0.53+32.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| (dollars in thousands, except per share amounts) | 2024 | 2023 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $51,870 | $42,925 |
| Inventories | 16,243 | 15,691 |
| Accounts receivable, net | 34,368 | 39,290 |
| Prepaid expenses and other current assets | 11,350 | 20,243 |
| Total current assets | 113,831 | 118,149 |
| Property and equipment, net | 2,200 | 3,629 |
| Operating right-of-use assets | 8,218 | 12,416 |
| Intangible asset, net | — | 36,042 |
| Goodwill | 59,044 | 59,044 |
| Other long-term assets | 37,377 | 12,423 |
| Total assets | $220,670 | $241,703 |
| Liabilities and stockholders' deficit | ||
| Current liabilities: | ||
| Accounts payable | $15,180 | $14,635 |
| Accrued expenses and other current liabilities | 63,460 | 67,735 |
| Current portion of long-term debt | — | 17,500 |
| Working Capital Fund liability, current portion | 2,274 | — |
| Total current liabilities | 80,914 | 99,870 |
| Long-term deferred revenue | — | 43,296 |
| Long-term operating lease liabilities | 3,547 | 8,947 |
| Long-term debt, net | 38,693 | 17,183 |
| Liability related to settlement royalties, net of current portion | 46,697 | — |
| Liability related to sale of future royalties, net of current portion | 52,066 | 54,013 |
| Working Capital Fund liability, net of current portion | 38,013 | 40,093 |
| Warrant liability | 5,176 | — |
| Other long-term liabilities | 4,749 | 8,885 |
| Total liabilities | 269,855 | 272,287 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' deficit: | ||
| Preferred stock $0.00001 par value, 25,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock: $0.00001 par value; 350,000,000 shares authorized at December 31, 2024 and 2023; 224,848,992 and 194,582,539 shares issued and outstanding at December 31, 2024 and 2023, respectively | 2 | 2 |
| Additional paid-in capital | 1,629,167 | 1,578,358 |
| Accumulated other comprehensive income | 6 | 6 |
| Accumulated deficit | (1,678,360) | (1,608,950) |
| Total stockholders' deficit | (49,185) | (30,584) |
| Total liabilities and stockholders' deficit | $220,670 | $241,703 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.